scholarly journals Mania possibly linked with bupropion for smoking cessation: A case report

2016 ◽  
Vol 6 (6) ◽  
pp. 314-317
Author(s):  
Stephanie Dwyer ◽  
Robin Hieber
Keyword(s):  
Smoking Cessation ◽  
Case Report ◽  
Electroconvulsive Therapy ◽  
Literature Search ◽  
Psychiatric History ◽  
First Case ◽  
Initiation Of Therapy ◽  
Minimal Information ◽  
Reduced Risk

Abstract Bupropion is an antidepressant thought to have a reduced risk of inducing mood switching as compared to other antidepressants. Minimal information is available on the induction of mood shifts when used for smoking cessation. This case describes a 38-year-old female who experienced mania following initiation of bupropion for smoking cessation. After completion of a thorough literature search, this appears to be the first case report describing mania induced by bupropion that was refractory to medications and was resolved with electroconvulsive therapy. This case highlights the need for clinicians to perform thorough histories of patients to avoid missing psychiatric history prior to starting bupropion as well as monitor for changes in mood or behavior after initiation of therapy.

scholarly journals A Case of Hypophosphatemiawith Increased Urinary Excretion of Phosphorus Associated with Ibrutinib

2016 ◽  
Vol 9 (1) ◽  
pp. 223-227 ◽  
Author(s):  
Ewa M. Wysokinska ◽  
Amanda M. Thompson ◽  
Carlos R. Franco Palacios
Keyword(s):  
Renal Function ◽  
Uric Acid ◽  
Case Report ◽  
Hematologic Malignancies ◽  
Lymphocytic Leukemia ◽  
Serum Phosphorus ◽  
Phosphorus Level ◽  
First Case ◽  
Initiation Of Therapy

Ibrutinib, an irreversible oral inhibitor of Bruton's tyrosine kinase, has been used in the treatment of patients with multiple hematologic malignancies. A 59-year-old male with chronic lymphocytic leukemia was treated with 420 mg/day of ibrutinib. No evidence of bruising or diarrhea was noted. The treatment was complicated by a transient increase in creatinine (from a baseline of 1.2 to 1.5 mg/dl) and potassium (reaching a peak of 6.5 mEq/l). Uric acid and calcium levels were normal. The patient developed hypophosphatemia (prior to initiation of therapy the serum phosphorus was 2.9 mg/dl). No metabolic acidosis was noted. Urinalysis showed no glucosuria or proteinuria. Urinary fraction of excretion of phosphate was found to be 345% (normal <5%). Because of these changes, ibrutinib was held, and the patient was given kayexalate. Serum potassium normalized. Serum phosphorus was checked a couple of weeks later and also normalized. A lower dose of ibrutinib (140 mg/day) was restarted. Upon follow-up, the phosphorus level has been between 2.9 and 3.2 mg/dl. No further evidence of hyperkalemia has been noted. Renal function has remained at baseline. To the best of our knowledge, this is the first case report describing the mechanism of hypophosphatemia in a patient treated with ibrutinib.

Granuloma Annulare as an Isotopic Response to Herpes Zoster

2014 ◽  
Vol 18 (6) ◽  
pp. 413-419 ◽  
Author(s):  
Jonathan Levy ◽  
Duane Barber ◽  
Lynne Robertson
Keyword(s):  
Case Report ◽  
Herpes Zoster ◽  
Skin Disease ◽  
Skin Disorder ◽  
Literature Search ◽  
Granuloma Annulare ◽  
Literature Report ◽  
First Case ◽  
The Right ◽  
New Skin

Background: Wolf's isotopic response is the phenomenon of a new skin disease occurring at the site of another unrelated and already healed skin disorder. Most cases in the literature report herpes zoster (HZ) as the original disease; however, the isotopic responses vary greatly. Including this case, our literature search revealed 32 cases of isotopic granuloma annulare (GA) following HZ. Case Report: An 82-year-old male presented with GA localized to the right T9 dermatome that later appeared at other sites on the trunk and extremities. The patient had an episode of shingles involving the same dermatome 4 years earlier. Discussion: To our knowledge, this is the first case report of GA occurring initially as an isotopic response in an HZ scar and subsequently becoming generalized. Thirty-eight percent (12 of 32) of patients with isotopic GA following HZ were immunocompromised, which is similar to the published rate of immunodeficiency in patients with HZ.

scholarly journals Acute hyponatremia with accompanying hyperammonemia secondary to divalproex sodium: A case report

2018 ◽  
Vol 8 (4) ◽  
pp. 191-194
Author(s):  
Ashley J. Maister ◽  
Gregory T. Bogart
Keyword(s):  
Case Report ◽  
Sodium Channels ◽  
Case Reports ◽  
Divalproex Sodium ◽  
Voltage Gated Sodium Channels ◽  
First Case ◽  
Antiepileptic Medication ◽  
Health Disorders ◽  
Initiation Of Therapy ◽  
Acute Hyponatremia

Abstract Divalproex sodium (DVP) is an antiepileptic medication that also has mood stabilizing properties for patients with mental health disorders. Currently, there are a small number of case reports discussing the incidence of hyponatremia that occurs as an adverse effect of DVP. After completion of a thorough literature search, we present the first case report describing acute hyponatremia with accompanying hyperammonemia secondary to DVP use. This case describes a 44-year-old male patient who experienced hyponatremia with accompanying hyperammonemia following initiation of DVP for schizoaffective disorder. This case highlights the need for clinicians to consider monitoring electrolytes, in addition to liver function and platelets, with the initiation of therapy or increase in daily dosage. Given the drug's action at voltage-gated sodium channels, changes in serum sodium could be expected.

Periprocedural Management of Electroconvulsive Therapy in Pregnancy during COVID-19 Outbreak: The First Case Report in Thailand

2021 ◽  
Vol 104 (8) ◽  
pp. 1381-1388
Keyword(s):  
Case Report ◽  
Electroconvulsive Therapy ◽  
Multidisciplinary Team ◽  
Retrospective Chart Review ◽  
Electrical Current ◽  
Safe Patient Care ◽  
Periprocedural Management ◽  
First Case ◽  
Prolonged Seizure ◽  
Psychotic Features

Objective: To described the periprocedural electroconvulsive therapy (ECT) management of a patient in the 3rd trimester of pregnancy, the ECT complications, and their treatment. Materials and Methods: A retrospective chart review was conducted of a 26-year-old parturient with bipolar I disorder with psychotic features during the coronavirus disease 2019 (COVID-19) outbreak. Case Report: The patient was admitted and scheduled for ECT. Fifteen ECT sessions (eight on her first admission, and another seven on a second admission) were performed. General anesthesia with endotracheal intubation was conducted after sufficient preoxygenation. Complications were observed: prolonged seizure, decreased fetal heart rate, and hypersecretion. Nonetheless, good outcomes were achieved after treated with thiopental to terminate the seizure, intravenous crystalloid loading and left uterine displacement to stabilize the fetus, and suctioning and an antisialagogue for secretion clearance. Conclusion: In ECT during pregnancy, it can be challenging to apply electrical current, induce anesthesia and airway management to achieve safe patient care and ensure adequate seizure duration. Moreover, the ECT is conducted in a non-operating room setting where equipment may be deficient. A prerequisite is good periprocedural collaboration among members of the multidisciplinary team which include a psychiatrist, an anesthesiologist, and an obstetrics-gynecologist, as well as proper protective equipment to prevent the contamination to the environment. Keywords: Coronavirus disease 2019 (COVID-19); Electroconvulsive therapy (ECT); Multidisciplinary team; Periprocedural management; Pregnancy

Catatonia LSD Induced?

1995 ◽  
Vol 29 (2) ◽  
pp. 324-327 ◽  
Author(s):  
K. M. H. Perera ◽  
A. Ferraro ◽  
M. R. M. Pinto
Keyword(s):  
Case Report ◽  
Electroconvulsive Therapy ◽  
Diagnostic Category ◽  
Lysergic Acid ◽  
Lysergic Acid Diethylamide ◽  
First Case ◽  
Catatonic Syndrome

The case of a patient who developed catatonia one week following Lysergic Acid Diethylamide (LSD) ingestion is presented. The psychosis developed two days after the intake. The catatonic syndrome resolved dramatically following one treatment of electroconvulsive therapy (ECT). This is perhaps the first case report of catatonia following the use of LSD. The need for a diagnostic category of organic catatonia is highlighted.

Reversible hearing loss associated with high-voltage electric shock

2005 ◽  
Vol 119 (8) ◽  
pp. 631-633 ◽  
Author(s):  
Pankaj Jindal ◽  
Anu N Nagarkar ◽  
S B S Mann
Keyword(s):  
Hearing Loss ◽  
Case Report ◽  
Sensorineural Hearing Loss ◽  
High Voltage ◽  
Current Literature ◽  
Electric Shock ◽  
Rare Entity ◽  
First Case ◽  
Minimal Information

Hearing loss associated with high-voltage electric shock is a rare entity and minimal information is available in the current literature about this condition. To our knowledge, this article represents the first case report in the literature of improvement in sensorineural hearing loss sustained due to a high-voltage electric shock.A case report of a patient who incurred various otologic problems, including hearing loss and tinnitus, is presented. An improvement in hearing loss and tinnitus was observed in the subsequent follow up after one month. Audiological findings and possible pathophysiology of hearing loss are discussed.We recommend that further studies be done to investigate the incidence, severity and pathophysiology of hearing loss in such cases.

scholarly journals Valacyclovir-associated Psychosis and Manic Symptoms in an Adolescent Female with Genital Herpes Simplex: A Case Report

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
S. Aslam ◽  
K. Carroll ◽  
B. Naz ◽  
A. Alao
Keyword(s):  
Drug Reaction ◽  
Case Report ◽  
Genital Herpes ◽  
Intravenous Route ◽  
Adolescent Female ◽  
Psychiatric History ◽  
Manic Symptoms ◽  
Cat Scan ◽  
First Case ◽  
Severity Of The Disease

We report the first case of valacyclovir-induced psychosis with symptoms of mania in an adolescent female with no psychiatric history. the patient presented with irritable mood, decreased need for sleep, auditory hallucinations, and grandiose delusions 72 hours after starting oral valacyclovir for newly acquired genital herpes. She was on no other medications. Delirium was ruled out by history and physical, urine toxicology was negative, head CAT scan was unremarkable, as were thyroid hormones and basic laboratories. the symptoms continued after stopping the valacyclovir, but improved with risperidone. after withdrawal of risperidone, the patient has been symptom free for 4 months. According to the Naranjo Adverse Drug Reaction (ADR) probability scale, this case report scores as a possible drug reaction. Although there are no reports of neuropsychiatric side effects with valacyclovir, there are for the medications structural analogs, acyclovir and ganciclovir. These cases were primarily in elderly patients who are immunocompromised, have renal dysfunction and receive the medication by the intravenous route. other anti-viral medications, such as interferon, have also been shown to induce mood symptoms, including depression and mania. Genital Herpes is a common and painful infection, with no known cure. Three medications, acyclovir, valacyclovir and famciclovir, have been shown to reduce the duration and severity of the disease. Clinicians should be aware that Valacyclovir and its analogs may induce psychosis with manic symptoms in young, healthy patients with no previous psychiatric history. Further research is needed to demonstrate a clear association, causal relationship and possible mechanism for the reaction.

A Case of Catatonia in a 14-Year-Old Girl with Schizophrenia Treated with Electroconvulsive Therapy

2013 ◽  
Vol 41 (1) ◽  
pp. 69-74 ◽  
Author(s):  
Frank Häßler ◽  
Olaf Reis ◽  
Steffen Weirich ◽  
Jacqueline Höppner ◽  
Birgit Pohl ◽  
...  
Keyword(s):  
Case Report ◽  
Treatment Response ◽  
Electroconvulsive Therapy ◽  
Rating Scale ◽  
Combined Treatment ◽  
Adolescent Patient

This article presents a case of a 14-year-old female twin with schizophrenia who developed severe catatonia following treatment with olanzapine. Under a combined treatment with amantadine, electroconvulsive therapy (ECT), and (currently) ziprasidone alone she improved markedly. Severity and course of catatonia including treatment response were evaluated with the Bush-Francis Catatonia Rating Scale (BFCRS). This case report emphasizes the benefit of ECT in the treatment of catatonic symptoms in an adolescent patient with schizophrenic illness.

The first case report of Pembrolizumab inducing thyroiditis and hypophysitis

2020 ◽  
Author(s):  
Rahman Maraqa Sima Abdel ◽  
Robert McMahon ◽  
Anusha Pinjala ◽  
Gastelum Alheli Arce ◽  
Mohsen Zena
Keyword(s):  
Case Report ◽  
First Case
Sign in / Sign up

Export Citation Format

Share Document